Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn’s disease: Results of the ACCEPT-OBI study

Anthony Buisson, Karim Gebara, MD, Bénédicte Caron, Gilles Boschetti, Cyrielle Gilletta de Saint Joseph, Maria Nachury, Hedia Brixi, Pascal Juillerat, Mélanie Serrero, Lucine Vuitton, Xavier Hebuterne, Ludovic Caillo, Antoine Blain, David Laharie, Laurent Peyrin-Biroulet, Romain Altwegg, Guillaume Le Cosquer, Bruno Pereira, and Mathurin Fumery, on behalf of the GETAID

Therapeutic Advances in GastroenterologyVolume 19, 2026 © The Author(s) 2026,Article Reuse Guidelines

https://doi.org/10.1177/17562848261489118